Compare ALCO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ALCO | MOLN |
|---|---|---|
| Founded | 1960 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 144.0M |
| IPO Year | 1994 | 2021 |
| Metric | ALCO | MOLN |
|---|---|---|
| Price | $41.17 | $4.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $44.00 | $8.38 |
| AVG Volume (30 Days) | ★ 15.4K | 2.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.50 | $3.41 |
| 52 Week High | $45.01 | $5.36 |
| Indicator | ALCO | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 41.60 |
| Support Level | $39.98 | $3.94 |
| Resistance Level | $41.96 | $4.54 |
| Average True Range (ATR) | 1.16 | 0.08 |
| MACD | -0.14 | -0.02 |
| Stochastic Oscillator | 48.05 | 0.00 |
Alico Inc is a Florida-based agribusiness and land management company that mainly focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers the majority of the revenue as the firm's primary operating business unit.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.